Section Arrow
VKTX.NASDAQ
- Viking Therapeutics
Quotes are at least 15-min delayed:2026/01/07 07:13 EST
Pre Market
Last
 32.44
+0.14 (+0.43%)
Bid
32.31
Ask
32.49
High 32.6 
Low 32.2 
Volume 4.33K 
Regular Hours (Closed)
Last
 32.3
+0.16 (+0.50%)
Day High 
33.28 
Prev. Close
32.14 
1-M High
39.08 
Volume 
3.70M 
Bid
32.31
Ask
32.49
Day Low
31.56 
Open
31.88 
1-M Low
31.85 
Market Cap 
3.63B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 35.61 
20-SMA 36.09 
50-SMA 36.34 
52-W High 43.15 
52-W Low 18.92 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.12/-3.53
Enterprise Value
3.63B
Balance Sheet
Book Value Per Share
6.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CYCNCyclerion Therapeutics1.95+0.57+41.30%-- 
Pre Market 1.91 -0.04 -2.05%
ALMSAlumis Inc.16.23+7.92+95.31%0.33PE
Pre Market 17.1 +0.87 +5.36%
MREOMereo BioPharma Group plc0.379-0.1016-21.14%-- 
Pre Market 0.4052 +0.0262 +6.91%
SLSSELLAS Life Sciences Group4.1-0.9-18.00%-- 
Pre Market 4.09 -0.01 -0.24%
RXRXRecursion Pharmaceuticals4.55+0.18+4.12%-- 
Pre Market 4.54 -0.01 -0.22%
Industry overview quotes are at least 15 minutes delayed
Business Description
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.